Maurie Markman, MD, discusses characterizing tumor types in ovarian cancer and treating the malignancy with checkpoint inhibitors.
Maurie Markman, MD, president of Medicine and Science, Eastern Regional Medical Center, discusses characterizing tumor types in ovarian cancer and treating the malignancy with checkpoint inhibitors. Markman says only recently have papers been published on checkpoint inhibitors in the treatment of ovarian cancers, marking just how far behind research is on the topic compared to other cancers.
Avutometinib/Defactinib Leads to Positive Response, Survival Data in Ovarian Cancer
October 18th 2024The completion of a new drug application for the combination of avutometinib and defactinib in KRAS-mutant ovarian cancer is expected to be finalized with the FDA by the end of the month.
Read More